In order to explore the effect of irisin on metastatic melanoma (MM) cell viability, we treated the MM cell lines HBLwt/wt, LND1wt/wt, Hmel1V600K/wt and M3V600E/V600E, characterized by the oncogenic activation of BRAF, with different concentrations of r-irisin, for 24 h and 48 h. The gene discussed is BRAF; the disease is Miyoshi myopathy.